HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 468.18% from the company’s current price.

A number of other research analysts also recently commented on the stock. Wells Fargo & Company decreased their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. UBS Group dropped their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Wedbush reissued a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Trading Down 5.9 %

NASDAQ ZNTL opened at $1.76 on Thursday. Zentalis Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $16.27. The stock has a 50 day moving average of $2.06 and a 200-day moving average of $2.87. The company has a market cap of $125.43 million, a PE ratio of -0.71 and a beta of 1.75.

Insiders Place Their Bets

In other news, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ingmar Bruns purchased 20,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZNTL. Corton Capital Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $32,000. Captrust Financial Advisors bought a new position in Zentalis Pharmaceuticals in the fourth quarter valued at about $33,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the third quarter worth about $37,000. Erste Asset Management GmbH bought a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $37,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at approximately $39,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.